Plasma matrix metalloproteinases (MMP-2 and MMP-9) as prognostic biomarkers in coronary heart disease

Marynenko, Tetiana; Halenova, Tetiana; Raksha, Nataliia; Vovk, Tetiana; Tyravska, Yuliya; Savchuk, О.; Falalyeyeva, Tetyana; Fagoonee, Sharmila; Abenavoli, Ludovico; Остапченко, Л. И.

doi:10.23736/s2724-542x.22.02906-6

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon ET A receptor activation, MMP-9 levels increase and, since MMP-9 can degrade the extracellular matrix [140], the dysregulation of MMP-9 activity may contribute to the pathological changes observed in the vasculature. MMP-9 has also been identified as a biomarker of the early stages of coronary heart disease [141]. Interestingly, a significant increase in aortic mRNA levels of ET-1 and MMP-9 have been observed in ApoE −/− mice exposed to petrol emissions and carbon monoxide [121].…”

Section: Air-pollution-induced Vascular Pathologymentioning

confidence: 99%

Endothelin-1 in Health and Disease

Banecki

Dora

2023

IJMS

View full text Add to dashboard Cite

Discovered almost 40 years ago, the potent vasoconstrictor peptide endothelin-1 (ET-1) has a wide range of roles both physiologically and pathologically. In recent years, there has been a focus on the contribution of ET-1 to disease. This has led to the development of various ET receptor antagonists, some of which are approved for the treatment of pulmonary arterial hypertension, while clinical trials for other diseases have been numerous yet, for the most part, unsuccessful. However, given the vast physiological impact of ET-1, it is both surprising and disappointing that therapeutics targeting the ET-1 pathway remain limited. Strategies aimed at the pathways influencing the synthesis and release of ET-1 could provide new therapeutic avenues, yet research using cultured cells in vitro has had little follow up in intact ex vivo and in vivo preparations. This article summarises what is currently known about the synthesis, storage and release of ET-1 as well as the role of ET-1 in several diseases including cardiovascular diseases, COVID-19 and chronic pain. Unravelling the ET-1 pathway and identifying therapeutic targets has the potential to treat many diseases whether through disease prevention, slowing disease progression or reversing pathology.

show abstract

Section: Air-pollution-induced Vascular Pathologymentioning

confidence: 99%

Endothelin-1 in Health and Disease

Banecki

Dora

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…It is noteworthy that one of the "most important general surgical problems of transplantology and cardiac sur-Gastroenterology Review 2023; 18 (4) gery remains the diagnosis and tactics of treatment of complications from the abdominal organs" [7]. Despite the low frequency of abdominal complications after heart surgery using artificial circulation (AC), estimated at only 0.4-5.0%, these complications lead to a fatal outcome in 28.4-60% of cases [7,8]. At the same time, it should be considered that postoperative intestinal paresis leads to an increase in pressure in the lumen of the digestive tract and in the abdominal cavity.…”

Section: Introductionmentioning

confidence: 99%

Pathogenetic justification of digestive tract dysfunction correction to reduce the risk of ventricular extrasystoles after coronary bypass grafting

Utegaliev,

Ermakhanova,

Sarsembayev

et al. 2023

View full text Add to dashboard Cite

Introduction In heart pathology, abdominal pathology is often detected, but due attention has not been paid to this issue, and algorithms for predicting, preventing, and correcting the coefficient of endothelial dysfunction (CED) after coronary artery bypass grafting (CABG) with the use of artificial circulation (AC) have not been developed. Aim To substantiate the pathogenetic expediency of correction of postoperative intestinal paresis after coronary artery bypass grafting for the prevention of functional cardiac complications. Material and methods 147 men were divided into 2 groups. Statistical processing of the obtained data was performed using Windows Microsoft Excel software and parametric methods of variational statistics, and the reliability of differences was determined using Student’s formula and table. Results It was found that in group II, after coronary artery bypass grafting, the clinical symptoms of intestinal dysfunction were significantly less ( p = 0.019), and the recovery of defecation was significantly faster ( p = 0.033) than in group I. After coronary artery bypass grafting, the frequency of high-grade extrasystoles in group II was significantly lower than in group I ( p = 0.033). Conclusions The application of the digestive tract dysfunction correction program is pathogenetically justified because it provides a reduction in the frequency of intestinal paresis and hence a reduction in the frequency of development of ventricular extrasystoles of high gradations after coronary artery bypass grafting.

show abstract